Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

University of Oxford Awarded £3 Million to Establish HealthTech Research Centre

The Nuffield Department of Primary Care Health Sciences wins an NIHR award for a new HealthTech Research Centre (HRC) to explore innovative Health Technology to enhance community and primary care.

OxCODE researchers at the Early Detection of Cancer Conference 2023

Oxford’s early detection research was featured at this annual event.

First private specialised haematology clinic and laboratory in sub-Saharan Africa launched

SerenOx Africa, led by Professor Anna Schuh, aims to address diagnostic gaps for common blood disorders through a testing facility for key underserved patient populations in Tanzania. This facility also aims to provide early cancer detection for high-risk patients.

Collaboration announced to develop the use of AI to evaluate Barrett’s oesophagus

An agreement between Satisfai Health Inc and the University of Oxford will progress the automated assessment of Barrett’s oesophagus with the aim of determining patients most at risk of developing oesophageal cancer.

OxCODE travel awards 2023

Congratulations to James Chettle, Masato Inoue and Eoghan Mulholland who have been awarded OxCODE funds to attend this year’s Early Detection of Cancer conference in London.

MILI trial: the start of precision cancer prevention

Oxford’s first precision prevention cancer trial in people with Li Fraumeni Syndrome will also shed light on the mechanisms of cancer development in the general population

Disentangling a long-standing link between inflammation and cancer progression

A study led by the Mead Group has demonstrated a previously unknown effect of chronic inflammation on TP53-mutant blood stem cells, shedding light on the progression of leukaemia.

OxCODE funding scheme awards 2023

Congratulations to James McCullagh, Monica Olcina, Bethan Psaila, and their collaborators who have been awarded funding in the fourth round of the OxCODE Funding Scheme.

Model to predict 10-year risk of breast cancer

A team of researchers led by Professor Julia Hippisley-Cox have developed a new model that reliably predicts a woman's likelihood of developing and then dying of breast cancer within a decade.

Double funding success to improve detection and risk classification of myeloproliferative neoplasms (MPNs)

Blood Cancer UK and Cancer Research UK recognise the need and impact of artificial intelligence approaches developed by Professor Daniel Royston and Professor Jens Rittscher for early detection and assessment of these blood cancers.

Identification of a molecular signature that correlates with patient prognosis in SETD2-mutated cancers

In a pan-cancer analysis spanning 24 different cancer types, researchers shed light on the relationship between SETD2, DNA methylation and cancer development.

New tool to predict people’s risks of getting oesophageal cancer

A new study from Professor Julia Hippisley-Cox and colleagues offers hope for the earlier detection of oesophageal cancer

NIHR to fund new Policy Research Unit on Cancer Awareness, Screening, and Early Diagnosis

The National Institute for Health and Care Research (NIHR) has announced a major investment in its Policy Research Units (PRUs). Researchers in the Nuffield Department of Primary Care Health Sciences at Oxford will play a key role in a new Unit focusing on the early detection of cancer.

Oxford to launch UK’s first trials unit dedicated to conducting precision prevention and early detection studies

Oxford researchers have been given a £1 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.

Professor David Hunter appointed as a Companion of the Order of Australia

David Hunter, Richard Doll Professor of Epidemiology and Medicine at Oxford Population Health and OxCODE Associate Director, has been appointed as a Companion of the Order of Australia in the Australian King’s Birthday Honours List.

Multi-cancer blood test shows real promise in NHS trial

An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.

Oxford DeLIVER research attracts 1000 patients for innovative Pearl clinical study

1000 patients have been recruited for the prospective Pearl study within the DeLIVER programme for early liver cancer detection.

Paresh Vyas and Julia Hippisley-Cox elected Fellow of Academy of Medical Sciences

The OxCODE members are two of eight Oxford researchers that have been elected to the Academy of Medical Sciences Fellowship.

New tool uses health records to predict risk of developing lung cancer within the next 10 years

A team of researchers from the University of Oxford and the University of Nottingham have developed ‘CanPredict’, a new tool able to identify those most at risk of developing lung cancer over the next 10 years, and put them forward for screening tests earlier, saving time, money and lives.

Prostate cancer AI diagnosis tool begins evaluation in Oxford

Researchers and clinicians in Oxford have begun an evaluation of artificial intelligence (AI) software that could help pathologists diagnose prostate cancer.

Load More